Kitasamycin CAS 1392-21-8 39405-35-1

Indoxacarb CAS 144171-61-9 173584-44-6
Pefloxacin CAS 70458-92-3
Show all

Model: MOS 1392-21-8 39405-35-1
CAS: 1392-21-8 39405-35-1
Molecular formula: C41H69NO13
Molecular weight: 783.99
Water solubility: ethanol: 50 mg/mL, clear to slightly hazy, light-yellow
Synonyms: Acetyl Kitasamycin
Refractive index: 1.532

Kitasamycin (CAS: 1392-21-8 39405-35-1)

Appearance A white or almost white powder Conform
Chemical reaction Positive Positive
LC Four test solution and the control 

solution appears A5, A4, A1, A13 

peak retention time consistent peaks

Four test solution and the control 

solution appears A5, A4, A1, A13 

peak retention time consistent peaks

Alkalinity 8.0 ~ 10.0 8.8
Residue on Ignition ≤ 0.5% 0.2%
Water ≤ 3.0% 1.8%
Kitasamycin components Kitasamycin A1: 3.0%-15.0% 10.4%
Kitasamycin A4: 5%-25% 11%
Kitasamycin A5: 35%-70% 48%
Kitasamycin A13: 3.0%-15.0% 7.9%
KitasamycinA (9+8+7+6+5+4+1+3+13): ≥85% 98%
Assay Not less than 1300u/mg calculated with reference

 to the anhydrous substances



Kitasamycin (INN) is a macrolide antibiotic. It is produced by Streptomyces kitasatoensis.  The medicine has

antimicrobial activity against a wide spectrum of pathogens. There are several generic names of this drug such

as- •Kitasamycin (OS: BAN, JAN, USAN) •Kitasamycine (OS: DCF) •C 637 (IS) •Katasamycin (IS) •Leucomycin

(IS) •Kitasamycin (PH: JP XV) •Kitasamycin Acetate (OS: JAN) •Leucomycin Acetate (IS) •Kitasamycin Acetate

(PH: JP XV) •Kitasamycin Tartrate (OS: JAN) •Leucomycin Tartrate (IS) •Kitasamycin Tartrate (PH: JP XV)

Antibacterial properties and erythromycin approximation of gram-positive bacteria, such as Staphylococcus aureus,

Streptococcus pyogenes, green streptococcus, Streptococcus pneumoniae, tetanus, diphtheria bacilli have a strong

inhibitory effect. Gram-negative bacteria, such as Neisseria gonorrhoeae, pertussis bacteria and other gram-negative

bacteria also have considerable extent. In addition, mycoplasma, leptospirosis, rickettsial inhibition. For most resistant

to penicillin and erythromycin are effective S. aureus is the product characteristics.

medicine use

Clinical mainly for upper respiratory tract infections, pneumonia, gonorrhea, cholecystitis,

whooping cough, tonsillitis and sepsis.

Dosage and Administration

0.8g ~ 1.2g / day, orally 4 times. Leucomycin tartrate injection for intravenous injection, dose 1 0.2g,

every 6 to 8 hours. Slow intravenous injection.


There are no reviews yet.

Be the first to review “Kitasamycin CAS 1392-21-8 39405-35-1”